CRS Jorge Heller Journal of Controlled Release Outstanding Paper Award

Co-sponsored by ELSEVIER

CRITERIA
The winning contribution must be an outstanding regular paper related to the science of controlled release (not an invited, a review, or from a special meeting) and published during 2007 in the Journal of Controlled Release.

SELECTION PROCESS
The Journal of Controlled Release Outstanding Paper Committee will make the selection of the awardee.

AWARD
The recipient will receive:

• $1,000 award
• Complimentary Annual Meeting and Exposition Registration
• Plaque

Jorge Heller Journal of Controlled Release Outstanding Paper Award 2008
Naoki Okada obtained Ph.D. from Osaka University in 1997. From 1997 to 1998 Okada was a research worker at the Biopharmaceutical and Pharmacokinetic Research Laboratories, Fujisawa Pharmaceutical Co., Ltd. and, from 1998 to 2005, was an assistant professor in the Department of Biopharmaceutics, Kyoto Pharmaceutical University. Okada has been an associate professor in the Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University since 2005 and in 2008 began work as a post-doctoral fellow at the Marlene and Stewart Greenebaum Cancer Center, University of Maryland. Okada’s work involves development and optimization of cell therapy, gene therapy, and immunotherapy based on drug delivery systems.

Shinsaku Nakagawa received a Ph.D. degree from Osaka University in 1993. From 1988 to 1993 Nakagawa was a research associate in the Faculty of Pharmaceutical Sciences, Kobe-Gakuin University. Nakagawa then moved on to the Department of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, holding positions as a research associate (1993–1994), assistant professor (1994–1999), associate professor (1999–2005), and professor (2005–present). Nakagawa’s research involves optimization of vaccine therapy for infectious disease and cancer and drug delivery systems for the development of cell therapy.

The paper: A strategy for efficient cross-presentation of CTL-epitope peptides leading to enhanced induction of in vivo tumor immunity